Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
Testosterone: Functions and Regulation01:26

Testosterone: Functions and Regulation

The intricate hormonal interplay essential for male reproductive health begins with the release of gonadotropin-releasing hormone (GnRH) by the hypothalamus. This hormone prompts the pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). LH targets the Leydig cells in the testes, stimulating them to produce and release testosterone. In concert with testosterone, FSH acts on the Sertoli cells within the seminiferous tubules to facilitate the release of...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Associations of testosterone, sex hormone-binding globulin, and related hormones with risks of cancer death, incident cancer, and incident prostate cancer in men: individual participant data meta-analyses.

The lancet. Healthy longevity·2026
Same author

Testosterone Treatment in Prostate Cancer Survivors With Hypogonadism: A Randomized Clinical Trial.

JAMA internal medicine·2026
Same author

Effects of Testosterone-Augmented Multimodal Exercise Intervention in Spinal Cord Injury: A Randomized Controlled Trial.

The Journal of clinical endocrinology and metabolism·2026
Same author

Number of Live Births as a Protective Factor Against Clinical and Covert Brain Infarcts: The Framingham Heart Study.

Journal of the American Heart Association·2026
Same author

Multiple dynamically-coupled binding sites on human serum albumin regulate estradiol's nonlinear binding.

Endocrinology·2026
Same author

Neighborhood Disadvantage and Recruitment and Retention of Participants in STRIDE, a Multi-Center Clinical Trial of Community-Living Older Persons.

Journal of the American Geriatrics Society·2026
Same journal

Seeing cachexia clearly: the evolution of body composition and radiological biomarkers in cancer wasting.

Current opinion in clinical nutrition and metabolic care·2026
Same journal

The updated recommendations for medical nutrition in the perioperative period: a focus on early oral intake.

Current opinion in clinical nutrition and metabolic care·2026
Same journal

Pediatric and adolescent nutritional and metabolic assessment in the precision era.

Current opinion in clinical nutrition and metabolic care·2026
Same journal

Nutrition in cirrhosis: bridging guidelines and practice in hepatic disease.

Current opinion in clinical nutrition and metabolic care·2026
Same journal

Metabolic health in a changing world: widening the lens to climate, cities, and place.

Current opinion in clinical nutrition and metabolic care·2026
Same journal

Beyond the scale: a systems-level reframing of obesity and metabolic care.

Current opinion in clinical nutrition and metabolic care·2026
See all related articles

Related Experiment Video

Updated: Jun 24, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Selective androgen receptor modulators as function promoting therapies.

Shalender Bhasin1, Ravi Jasuja

  • 1Section of Endocrinology, Diabetes, and Nutrition, Boston Claude D. Pepper Older Americans Independence Center for Function Promoting Therapies, Boston University School of Medicine, Boston, Massachusetts, USA. Bhasin@bu.edu

Current Opinion in Clinical Nutrition and Metabolic Care
|April 10, 2009
PubMed
Summary
This summary is machine-generated.

Selective androgen receptor modulators (SARMs) show promise for improving muscle and bone health. These compounds offer potential anabolic therapies for age-related decline and chronic diseases.

More Related Videos

Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

Related Experiment Videos

Last Updated: Jun 24, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

Area of Science:

  • Endocrinology
  • Pharmacology

Background:

  • Selective androgen receptor modulators (SARMs) are being developed to improve physical function and bone health.
  • The goal is to enhance anabolic effects without adverse prostate and cardiovascular outcomes.

Purpose of the Study:

  • To review the historical development and rationale behind SARM research.
  • To explain the mechanisms of testosterone action and SARM selectivity.

Main Methods:

  • Review of historical data and preclinical studies on steroidal and nonsteroidal SARMs.
  • Analysis of SARM interactions with the androgen receptor (AR) and coregulators.
  • Examination of Phase I human trial data.

Main Results:

  • Nonsteroidal SARMs act as full agonists in muscle and bone, and partial agonists in the prostate.
  • SARMs demonstrate tissue-specific gene regulation through AR conformational changes.
  • Preclinical studies show increased muscle and bone mass, with some prostate sparing.
  • Human trials report modest increases in fat-free mass.

Conclusions:

  • SARMs represent a promising new class of anabolic therapies.
  • Potential applications include functional limitations in aging, chronic disease, frailty, cancer cachexia, and osteoporosis.